GRI Bio, Inc. (NASDAQ: VLON), (“GRI,” “GRI Bio,” or the “Company”), has announced the completion of the previously announced merger between Vallon Pharmaceuticals, Inc. (now GRI Bio, Inc.) and GRI Bio, Inc. (now GRI Bio Operations, Inc. and referred to herein as “Private GRI”), a privately held biotechnology company. The combined company will operate under the name “GRI Bio, Inc.” and will focus on advancing GRI Bio’s innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases.
Read the full article: Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc. //
Source: https://www.globenewswire.com/news-release/2023/04/21/2652134/0/en/Vallon-Pharmaceuticals-Completes-Merger-with-GRI-Bio-Inc.html